• Published On : Jun-2015 |
  • Pages : 71 Pages |
  • Format :

Chapter 1 Preface 8

1.1 Report Description 8

1.2 Research Methodology 9

1.3 Assumptions 9

Chapter 2 Market Synopsis 10

Chapter 3 Porter’s Five Forces Analysis 11

3.1 Bargaining Power of Suppliers 11

3.2 Bargaining Power of Buyers 12

3.3 Threat of New Entrants 12

3.4 Threat of Substitutes 12

3.5 Intensity of Rivalry 13

Chapter 4 Industry Overview 14

4.1 Market Definition 14

4.2 Market Drivers 16

      4.2.1 Rising geriatric population 16

      4.2.2 Change in lifestyle impinging bone health 17

      4.2.3 Increasing prevalence of osteoporosis in post-menopausal women 18

      4.2.4 Increasing awareness about osteoporosis care 19

      4.2.5 Increasing R&D investments in drug discovery and development 20

4.3 Impact Analysis of Market Drivers 20

4.4 Market Restraints 21

      4.4.1 Side effects and complications associated with administration of osteoporosis drugs 21

      4.4.2 Patent expiration of osteoporosis drugs 22

4.5 Impact Analysis of Market Restraints 23

Chapter 5 Global Market Size and Forecast 24

Chapter 6 Market Size and Forecast by Drug Type 28

6.1 Bisphosphonates 28

6.2 Parathyroid Hormone Therapy Drugs 30

6.3 Calcitonin 32

6.4 Selective Estrogen Receptor Modulators (SERMs) 34

6.5 RANK Ligand Inhibitors (Denosumab) 36

Chapter 7 Market Size and Forecast by Geography 39

7.1 North America 39

7.2 Europe 41

7.3 Asia Pacific 44

Chapter 8 Competitive Scenario 48

8.1 Competitive Analysis 48

Chapter 9 Company Profiles 50

9.1 Eli Lilly and Company 50

      9.1.1 Company overview 50

      9.1.2 Products and services 50

      9.1.3 Financial performance 51

      9.1.4 Key developments 51

9.2 F. Hoffmann-La Roche Ltd 52

      9.2.1 Company overview 52

      9.2.2 Products and services 52

      9.2.3 Financial performance 53

      9.2.4 Key developments 53

9.3 Merck & Co. Inc. 54

      9.3.1 Company overview 54

      9.3.2 Products and services 54

      9.3.3 Financial performance 55

      9.3.4 Key developments 55

9.4 Novartis AG 56

      9.4.1 Company overview 56

      9.4.2 Products and services 56

      9.4.3 Financial performance 57

      9.4.4 Key developments 57

9.5 Amgen, Inc. 58

      9.5.1 Company Overview 58

      9.5.2 Product and Services 58

      9.5.3 Financial Performance 58

      9.5.4 Recent Developments 59

9.6 Novo Nordisk A/S 60

      9.6.1 Company overview 60

      9.6.2 Products and services 60

      9.6.3 Financial performance 61

      9.6.4 Key developments 61

9.7 Actavis plc 62

      9.7.1 Company overview 62

      9.7.2 Products and services 62

      9.7.3 Financial performance 62

      9.7.4 Key developments 63

9.8 Pfizer, Inc 65

      9.8.1 Company overview 65

      9.8.2 Products and services 65

      9.8.3 Financial performance 66

      9.8.4 Key developments 66

9.9 GlaxoSmithKline plc 67

      9.9.1 Company overview 67

      9.9.2 Products and services 67

      9.9.3 Financial performance 68

      9.9.4 Key developments 68

9.10 Teva Pharmaceutical Industries Ltd. 69

      9.10.1 Company overview 69

      9.10.2 Products and services 69

      9.10.3 Financial performance 70

      9.10.4 Key developments 70


List of Table

TABLE 1 Market snapshot: osteoporosis drugs market, 2015and 2022 10

TABLE 2 Drivers for osteoporosis drugs market: Impact analysis 20

TABLE 3 Patent expiration of various osteoporosis drugs 22

TABLE 4 Restraints for global osteoporosis drugs market: Impact analysis 23

TABLE 5 Global osteoporosis drugs market size, by region, 2012 – 2014 (US$ Mn) 24

TABLE 6 Global osteoporosis drugs market size, by region, 2015 – 2022 (US$ Mn) 25

TABLE 7 Global osteoporosis drugs market size, by type, 2012 – 2014 (US$ Mn) 26

TABLE 8 Global osteoporosis drugs market size, by type, 2015 – 2022 (US$ Mn) 27

TABLE 9 Risk reduction of fracture with bisphosphonates over 3–4 years 28

TABLE 10 Global bisphosphonates drugs market size, by region, 2012 – 2014 (US$ Mn) 29

TABLE 11 Global bisphosphonates drugs market size, by region, 2015 – 2022 (US$ Mn) 30

TABLE 12 Global parathyroid hormone therapy drugs market size, by region, 2012 – 2014 (US$ Mn) 31

TABLE 13 Global parathyroid hormone therapy drugs market size, by region, 2015 – 2022 (US$ Mn) 32

TABLE 14 Global calcitonin drugs market size, by region, 2012 – 2014 (US$ Mn) 33

TABLE 15 Global calcitonin drugs market size, by region, 2015 – 2022 (US$ Mn) 34

TABLE 16 Global SERMs drugs market size, by region, 2012 – 2014 (US$ Mn) 35

TABLE 17 Global SERMs drugs market size, by region, 2015 – 2022 (US$ Mn) 36

TABLE 18 Global RANK ligand inhibitors drugs market size, by region, 2012 – 2014 (US$ Mn) 37

TABLE 19 Global RANK ligand inhibitors drugs market size, by region, 2015 – 2022 (US$ Mn) 38

TABLE 20 North America osteoporosis drugs market size, by country, 2012 – 2014 (US$ Mn) 40

TABLE 21 North America osteoporosis drugs market size, by country, 2015 – 2022 (US$ Mn) 41

TABLE 22 Europe osteoporosis drugs market size, by country, 2012 – 2014 (US$ Mn) 43

TABLE 23 Europe osteoporosis drugs market size, by country, 2015 – 2022 (US$ Mn) 44

TABLE 24 Asia Pacific osteoporosis drugs market size, by country, 2012 – 2014 (US$ Mn) 46

TABLE 25 Asia Pacific osteoporosis drugs market size, by country, 2015 – 2022 (US$ Mn) 47

TABLE 26 Major products of Eli Lilly and Company 50

TABLE 27 Major products of F. Hoffmann-La Roche, Ltd. 52

TABLE 28 Major products of Merck & Co., Inc. 54

TABLE 29 Major products of Novartis AG 56

TABLE 30 Major products of Amgen, Inc. 58

TABLE 31 Major products of Novo Nordisk A/S 60

TABLE 32 Major products of Actavis plc 62

TABLE 33 Major products of Pfizer, Inc. 65

TABLE 34 Major products of GlaxoSmithKline plc 67

TABLE 35 Major products of Teva Pharmaceutical Industries Ltd. 69


List of Figure

FIG. 1 Osteoporosis drugs market: Porter’s five force analysis 11

FIG. 2 Risk factors for osteoporosis 14

FIG. 3 Prevention of osteoporosis 15

FIG. 4 Aging population in major regions, 2000 – 2050 (% share in total population) 17

FIG. 5 Decrease of bone mass with onset of menopause 19

FIG. 6 Global osteoporosis drugs market share, by region, by value, 2014 24

FIG. 7 Global osteoporosis drugs market share, by type, by value, 2014 26

FIG. 8 Global bisphosphonates drugs market share, by region, by value, 2014 29

FIG. 9 Global parathyroid hormone therapy drugs market share, by region, by value, 2014 31

FIG. 10 Global calcitonin drugs market share, by region, by value, 2014 33

FIG. 11 Global SERMs drugs market share, by region, by value, 2014 35

FIG. 12 Global RANK ligand inhibitors drug market share, by region, by value, 2014 37

FIG. 13 North Americaosteoporosis drugs market share, by country, by value, 2014 40

FIG. 14 Number of hip fracture cases in European Union member states, 2000 – 2050 42

FIG. 15 Number of vertebra fracture cases in European Union member states, 2000 – 2050  42

FIG. 16 Europe osteoporosis drugs market share, by country, by value, 2014 43

FIG. 17 Asia Pacific osteoporosis drugs market share, by country, by value, 2014 46

FIG. 18 Drug focus analysis of osteoporosis drugs market 48

FIG. 19 Revenue and net income of Eli Lilly and Company, 2012–2014 (US$ Mn) 51

FIG. 20 Sales and net income of F. Hoffmann-La Roche, Ltd., 2012–2014 (US$Mn) 53

FIG. 21 Sales and net income of Merck & Co., Inc., 2012–2014 (US$Mn) 55

FIG. 22 Net sales and net income of Novartis AG, 2012–2014 (US$Mn) 57

FIG. 23 Total revenue and net income of Amgen, Inc., 2012–2014 (US$Mn) 59

FIG. 24 Novo Nordisk’s net sales and net profit, 2012 – 2014 (US$ Mn) 61

FIG. 25 Net revenue and net income of Actavis plc, 2012–2014 (US$ Mn) 63

FIG. 26 Revenue and net income of Pfizer, Inc., 2012–2014 (US$Mn) 66

FIG. 27 Turnover and total profit attributable to stakeholders of GlaxoSmithKline plc, 2012–2014 (US$Mn) 68

FIG. 28 Net revenue and net income of Teva Pharmaceutical Industries Ltd., 2012–2014 (US$Mn) 70